



Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET

1

OF

3

Complete if Known

Application Number: To Be Assigned

Filing Date: September 20, 2001

First Named Inventor: Chang, Nancy

Group Art Unit: To Be Assigned

1635

Examiner Name: To Be Assigned

Attorney Docket Number: TNX00-08

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number	Kind Code (if known)			
J3	5,762,943	B1	Dolovich	06-09-1998	
	6,239,116	B1	Kreig	05-29-2001	
	5,614,611	B1	Chang	03-25-1997	
	5,422,258	B1	Chang	06-06-1995	
	5,543,144	B1	Chang	08-06-1996	
	5,428,133	B1	Chang	06-27-1995	
	5,449,760	B1	Chang	09-12-1995	

FOREIGN DOCUMENTS

Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Tran.
	Office	Number	Kind Code (if known)				
J3	WO	92/21031	A1	De Weck, Alain	11-26-1992		N/A
	WO	92/17207	A1	Chang et al.	10-15-1992		N/A
	WO	00/16804	A1	Dina, Dino	03-30-2000		N/A
	WO	98/16247	A1	Carson et al.	04-23-1998		N/A
	WO	97/33616	A1	MacGlashan et al.	09-18-1997		N/A
	WO	98/24808	A2	Padlan, et al.	06-11-1998		N/A

Examiner
Signature

Date
Considered

9/20/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

SHEET 2 OF 3

Complete if Known

Application Number: To Be Assigned

Filing Date: September 20, 2001

First Named Inventor: Chang, Nancy

Group Art Unit: To Be Assigned 1635

Examiner Name: To Be Assigned

Attorney Docket Number: TNX00-08

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Documents		U.S. Patent Document Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number	Kind Code (if known)			
<u>J3</u>	5,965,709	B1	Presta et al.	10-12-1999	
	4,171,299	B1	Hamburger	10-16-1979	

FOREIGN DOCUMENTS

Examiner Initials	Foreign Patent Documents			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
	Office	Number	Kind Code (if known)				
<u>J3</u> ↓	WO	00/50460	A1	Dyson et al.	08-31-2000		N/A
	WO	97/22364	A1	Fishman et al.	06-26-1997		N/A
	EP	0263655	A2	Nakamura et al.	04-13-1988		N/A
	EP	0550020	A2	Washida et al.	07-07-1993		N/A

Examiner Signature	<u>J3</u>	Date Considered	<u>9/20/03</u>
-----------------------	-----------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

SHEET

3

OF

3

Complete if Known

Application Number: T B Assigned

Filing Date: September 20, 2001

First Named Inventor: Chang, Nancy

Group Art Unit: To Be Assigned

Examiner Name: To Be Assigned

Attorney Docket Number: TNX00-08

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T 2
J3		Heusser et al., "Therapeutic Potential of anti-IgE Antibodies", <i>Current Opinions in Immunology</i> 9(6):805-813 (1997).	
		Hook, W.A., et al., "Monoclonal Antibodies Defining Epitopes on Human IgE", <i>Mol. Immunol.</i> 28(6):631-639 (1991).	
		Spiegelberg, et al., "Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligonucleotides" <i>Allergy</i> vol. 53, pp. 93-97 (Sept. 1998).	
		Voo, K.S. et al., Cloning of a Mammalian Transcriptional Activator That Binds Unmethylated CpG Motifs and Shares a CXXC Domain with DNA Methyltransferase, Human Trithorax, and Methyl-CpG Binding Domain Protein 1," <i>Mol. Cell Biol.</i> 20(6):2108-2121 (2000).	
		Kreig, A.M., The Role of CpG Motifs in Innate Immunity," <i>Crr. Opin. Immunol.</i> 12:35-43 (2000).	
		McDonnell, J.M. et al., "Structure based design and characterization of peptides that inhibit IgE binding to its high affinity receptor," <i>Nature Struct. Biol.</i> 3(5):419-426 (1996).	
		Weigand, T.W. et al., "High Affinity Oligonucleotide Ligands to Human IgE Inhibit Binding to Fcε Receptor I," <i>J. Immunol.</i> 157:221-230 (1996).	
Examiner Signature	J3	Date Considered	9/20/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.